secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001437749-25-020102
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex secures $12.5M equity line with Lincoln Park; provides clinical trial updates
--------------------------------------------------------------------------------

- Entered purchase agreement for up to $12.5M in common stock; issued 1,186,859 commitment shares to Lincoln Park.
- Acclaim-1 Phase 2a expansion targets ~33 patients; interim analysis of first 19 expected Q1 2026, top-line in H1 2026.
- Acclaim-3 Phase 2 expansion plans ~50 patients; futility analysis after 25 patients expected Q1 2026.
- Both Acclaim-1 and Acclaim-3 have FDA Fast Track designation; Acclaim-3 also has Orphan Drug Designation.
- Proceeds from Lincoln Park sales to be used for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925020102/0001437749-25-020102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925020102/gnpx20250606c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-020102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer